Nexalin Acquires AI Platform for $1.3M to Support 160-Patient Trial
Nexalin acquired PONM, the AI-integrated digital health platform behind HALO Clarity and NeuroCare, for $1.3 million in stock to secure exclusive rights over remote monitoring, clinical-data capture and virtual-clinic infrastructure. The platform, deployed at UCSD, will support data workflows for a 160-participant FDA pivotal insomnia trial starting Q2 2026.
1. Acquisition Details and Platform Ownership
Nexalin closed its acquisition of PONM from GreenLight Ventures for $1.3 million in common stock, securing exclusive rights to the proprietary software features underpinning its HALO Clarity and Nexalin NeuroCare programs. The AI-integrated platform provides remote patient monitoring, treatment-compliance data capture, EHR functionality, virtual-clinic management and real-time analytics.
2. Deployment at UCSD and Trial Support
The PONM platform is already deployed at the University of California, San Diego, where it supports HALO headset usage tracking, remote prescribing and clinical research workflows. It will power recruitment and data workflows for a planned 160-participant FDA pivotal trial of HALO Clarity in moderate-to-severe insomnia set to start in Q2 2026.
3. Transaction Structure and Strategic Partnership
GreenLight Ventures becomes a substantial Nexalin equity holder under a strategic partnership that grants continued access to product engineering, quality assurance, cybersecurity, regulatory and commercial development capabilities. The stock-based payment structure, tied to Nexalin’s market performance, aligns GreenLight’s economics with the long-term success of HALO Clarity and NeuroCare.